HIGHLIGHTS Assays confirm the Company's maiden drillhole, RIBN-DD-001, at the RIB North Discovery as the best exploration hole drilled to date at the Angilak Uranium Project; RIBN-DD-001 assays returned total composite uranium mineralization1 of 34.7 m encompassing seven zones from 287.0 m to 439.9 m (Figure 4) - surpassing what was reported in the release of preliminary results (September 23rd, 2025, News Release ); The widest continuous intersection in the hole - from 426.3 to 439.9 - returned 13.6 m of c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the transition period from ____ to ____ Commission File Number: 001-39503 FORM 10-Q Athira Pharma, Inc. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) For the quarterly period ended September 30, 2025 Delaware 45-3368487 OR (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O ...

Exhibit 99.1 Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update • Athira conducted the first-in-human Phase 1 (NCT 06432647) double-blind, placebo- controlled clinical trial that enrolled 80 healthy volunteers to evaluate single and multiple oral ascending doses of ATH-1105. The study was completed in November 2024 and evaluated the safety and tolerability of ATH-1105 and included measurements of pharmacokinetic outcomes. Corporate Updates Financial Results Continuing to ...

Core Viewpoint - Athira Pharma is focused on maximizing stockholder value while advancing the clinical development of ATH-1105, a potential therapy for ALS, which has shown promising safety and pharmacokinetic profiles in Phase 1 trials [2][4]. Clinical Development & Pipeline Programs - Athira's pipeline includes small molecule drug candidates that target the neurotrophic hepatocyte growth factor (HGF) system, which is involved in neuroprotection and anti-inflammatory pathways in the central nervous system [3]. - ATH-1105 is designed to modulate the HGF system and is currently in clinical development for ALS, Alzheimer's disease, and Parkinson's disease [4]. Clinical Trial Results - The Phase 1 clinical trial of ATH-1105 enrolled 80 healthy volunteers and demonstrated a favorable safety profile, tolerability, dose proportional pharmacokinetics, and CNS penetration [7]. - Preclinical models of ALS have shown consistent beneficial effects from ATH-1105, including improvements in nerve and motor function, inflammation biomarkers, and survival rates [7]. Financial Results - As of September 30, 2025, Athira reported cash, cash equivalents, and investments of $25.2 million, down from $51.3 million at the end of 2024 [10]. - Research and Development (R&D) expenses for the quarter were $2.8 million, significantly lower than $17.9 million for the same period in 2024 [10]. - The net loss for the quarter was $6.6 million, or $1.68 per share, compared to a net loss of $28.7 million, or $7.46 per share, in the previous year [10][14]. Corporate Updates - Athira is exploring strategic alternatives to enhance stockholder value and has engaged Cantor Fitzgerald & Co. as an advisor in this process [7]. - A 10-for-1 reverse stock split was implemented on September 17, 2025, to potentially improve the stock's marketability [7].

Core Viewpoint - ATHA Energy Corp. has filed its final short form prospectus with various Canadian securities commissions, indicating progress in its private placement efforts [1] Group 1 - The company has received a receipt from the British Columbia Securities Commission, which acts as the principal regulator for this filing [1] - The prospectus qualifies up to 18,838,752 units that can be issued upon the exercise of 17,126,138 special warrants [1] - This filing is a follow-up to the company's previous announcement made on October 21, 2025, regarding its private placement [1]

Group 1 - ATHA Energy Corp. has filed its annual information form for the fiscal year ended December 31, 2024 [1] - The company has also filed a preliminary short form prospectus with securities commissions in multiple provinces [1] - The prospectus is related to the qualification of up to 18,838,752 units issuable upon the exercise of 17,126,138 special warrants [1]

Core Points - ATHA Energy Corp. is issuing a news release to clarify its disclosure regarding the Angilak Project following a review by the British Columbia Securities Commission (BCSC) [1] - The BCSC review identified deficiencies in the Company's prior technical disclosure, particularly concerning historical mineral resource estimates and the exploration target model [1]

Core Insights - A major new discovery has been made within the Mineralized RIB Corridor (MRC), specifically the RIB North Discovery, located approximately 1.4 km from the nearest drillhole at the RIB East Discovery [1] - The first drillhole at RIB North, RIBN-DD-001, has yielded the most robust mineralized intersection to date within the MRC and is considered one of the most significant intersections within the Angilak Uranium Project [1] - Drillhole RIBN-DD-001 intersected a total of 26.3 meters of composite uranium mineralization, including 1.9 meters of high-grade mineralization, across over 10 zones from 345.55 meters to 460.05 meters [1] - The hole featured 13.6 meters of continuous mineralization from 426.25 meters to 439.85 meters, which included 1.7 meters of high-grade mineralization with a maximum radioactivity of 55,730 counts per second (CPS) [1] - Mineralization was initially encountered directly above the unconformity at 356.7 meters, extending into graphitic basement rock [1]

Core Insights - ATHA has successfully closed a previously announced CAD $11.5 million over-subscribed bought deal [1] - The first two drill holes at the RIB West Discovery have intersected uranium mineralization over a strike length of approximately 340 meters [1] - This marks the third new discovery of uranium mineralization during the 2025 Angilak Exploration Program within the Angikuni Basin [1] - The RIB East Discovery is defined by eight mineralized drill holes, indicating shallow uranium mineralization across 7 million acres [1] - ATHA holds a 10% carried interest in key exploration projects in the Athabasca Basin operated by NexGen Energy Ltd [1]

Core Points - Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on therapies for neurodegenerative diseases [1] - A reverse stock split will occur on September 18, 2025, consolidating shares at a ratio of 1-for-10, approved by stockholders [1][2] - The reverse stock split aims to enhance the stock's marketability and potentially attract more investors [1][4] Stock Performance - Currently, ATHA's stock is priced at $0.38, with a slight increase of 0.29% or $0.0011 [3] - The stock has shown volatility, with a low of $0.35 and a high of $0.40 on the current trading day [3] - Over the past year, ATHA's stock has fluctuated between a high of $0.83 and a low of $0.22 [3] Market Capitalization and Trading Volume - Athira Pharma's market capitalization is approximately $15.1 million [4] - The trading volume on the NASDAQ exchange is 586,605 shares [4] - The reverse stock split may reduce the number of shares outstanding, potentially increasing the stock price [4]